Dear friends,
October is ending with seven candidates seeking to lead the WHO, 53 governments agreeing on the future of AI in healthcare, and Christine Lagarde explaining that her facial bandages are the result of treatment for a small skin cancer, rather than kick-boxing in Thailand. Given the current state of European politics, the latter might have been the safer sport.
But is the Élysée Palace calling from afar? Lagarde insists she is not a presidential candidate, although French politics has a habit of transforming yesterday’s impossibilities into tomorrow’s necessities. Could she become the unlikely middle-power candidate?
Middle powers are certainly fashionable these days. Ursula von der Leyen and António Costa have been in Montréal with Mark Carney, exploring how countries caught between great powers might reclaim influence. Europe’s establishment appears increasingly enthusiastic about the political middle ground abroad, just as it struggles to defend that ground at home. Perhaps strategic autonomy is easier across the Atlantic than across the European electorate.
And that brings us to the familiar theatre of electoral politics. Before elections, almost everything is possible: better healthcare, greater innovation, stronger economies and, naturally, lower taxes. Afterwards, the vocabulary changes to fiscal constraints, competing priorities and difficult choices.
The promises are universal. The budgets are selective.
Healthcare is where this contradiction becomes particularly uncomfortable.
In the United States, wider access to certain unapproved peptide injections is being encouraged despite serious questions about safety and effectiveness. Meanwhile, families face rising insurance premiums, growing deductibles and increasingly difficult decisions about whether they can afford medical care. Apparently, the freedom to try something unproven is expanding faster than the ability to obtain something proven.
Governments are equally enthusiastic about artificial intelligence. Yet emerging evidence suggests that patients may communicate symptoms differently when interacting with chatbots, while some AI systems appear inclined to recommend particular medicines, potentially increasing costs. An algorithm may process millions of data points, but it cannot resolve the political question of who pays when its recommendation is unaffordable.
Evidence from cancer immunotherapy also raises questions about differences in adverse events across populations. Research on brain health in Africa reminds us that income, education and nutrition influence health long before a prescription is written. Meanwhile, African governments are asking who controls the health data generating tomorrow’s innovations.
There is progress, of course. A cheaper malaria vaccine could protect more children. A simpler rare-disease treatment could transform daily life. New biomarker-guided cancer therapies are opening possibilities previously unavailable to patients. And Japan’s reassessment of a gene therapy after five years reminds us that innovation requires evidence and accountability.
But here lies the fundamental political problem.
We celebrate innovation at the point of scientific discovery and quietly ration it at the point of delivery.
We speak of personalised medicine while financing systems that remain remarkably indifferent to individual circumstances. We promise prevention while rewarding late intervention. We celebrate data-driven healthcare while struggling to finance the diagnostics that make it possible. And we encourage scientific cooperation while trade policy and geopolitical competition increasingly determine where resources flow.
From China and Brazil to Africa, Europe and the Middle East, health systems face different circumstances but the same fundamental challenge: translating scientific progress into accessible, trustworthy and sustainable care.
Perhaps the middle-power conversation should extend beyond geopolitics. The countries shaping tomorrow’s healthcare may not be those promising the most, but those combining scientific excellence, investment, public trust and the political courage to deliver.
While politicians debate strategic autonomy and competitiveness, patients depend on something considerably less fashionable: a functioning health system that can diagnose them, treat them and afford to do both.
Science determines what is possible. Politics determines what is affordable. And patients discover the difference.
This week’s question is therefore not simply who writes the rules, but who controls the money, who accepts responsibility, and why patients so often receive the bill for promises made by others.
Because the next dose is a political decision. And unlike an election promise, a patient cannot always wait another five years.
This week’s question is simple: who sets the terms, and can patients live with them?
This week, the stamp meets reality
- WHO’s next boss inherits the bill: Seven candidates enter a contest that will shape global health priorities and financing.
- Forty per cent off has a million children behind it: A malaria-vaccine deal could make limited immunisation budgets reach further.
- The cancer drug comes with a genetic gate: A new prostate-cancer approval depends on finding the relevant DNA-repair mutations.
- The drug middleman has to open the books: US regulators want large employer plans to see how pharmacy benefit managers are paid.
- The algorithm has met 53 health ministers: A regional AI roadmap puts governance, data quality and clinical value on the agenda.
- Africa wants the keys to its health data: A continental framework advances, with adoption and implementation still ahead.
- Japan asks a gene therapy for its receipts: A five-year evidence collection period gives way to a renewed value assessment.
- A rare-disease medicine leaves the refrigerator: A new risdiplam formulation could make treatment less demanding at home.
- The tumour found an escape route. The trial followed: A lung-cancer study shows why a second biomarker can change the next treatment decision.
| This is not another health news digest. It’s a twice-weekly readout of where evidence meets power and where power must turn into action. |
WHO’s next boss inherits the bill
Seven candidates have been proposed to become the next WHO Director-General: Hanan Mohammed Al-Kuwari, Hanan Balkhy, Hans Henri P. Kluge, María P. Neira, Budi Gunadi Sadikin, Li Song and Gevorg Tamamyan. They will meet Member States at a public candidates’ forum on 18–19 November. The Executive Board will narrow the field in 2027, ahead of the World Health Assembly’s appointment in May. (WHO)
The campaign will be a test of priorities as much as personalities. Member States should press each candidate on how WHO would support outbreak response, sustain essential programmes and help countries turn guidance into care when budgets are tight. Patients cannot use a well-worded global recommendation unless someone can finance and deliver it. The first forum offers a chance to ask what each contender would do when those obligations compete.
Forty per cent off has a million children behind it
UNICEF and Gavi have agreed a deal expected to cut the price of the RTS,S malaria vaccine by about 40%, to €5.50 a dose. UNICEF estimates savings of around US$50 million from 2027 to 2029. In one possible use of that money, up to one million additional children could receive the full four-dose course. The lower price depends on manufacturing and regulatory milestones, including WHO prequalification of a new production facility. (UNICEF)
This is what a price negotiation looks like when the unit of account is a child who might be reached. The advance financing behind the agreement gives the manufacturer a route to greater supply while giving immunisation programmes more purchasing power. The million-child figure is a possibility, not a delivery count: countries will still need doses, staff, funding and follow-up for all four appointments. Watch whether the facility clears its milestones and whether the savings become vaccinations.
The cancer drug comes with a genetic gate
The FDA has approved talazoparib with enzalutamide for adults with metastatic prostate cancer carrying specified homologous recombination repair, or HRR, gene mutations who are naïve or sensitive to androgen-pathway modulation. In the 599-patient TALAPRO-3 trial, the combination reduced the measured risk of radiographic progression or death compared with enzalutamide alone. Overall-survival data were immature at the time of analysis. (FDA)
The approval gives eligible patients an earlier biomarker-guided option. It also gives cancer services a practical assignment: obtain a suitable tissue or blood-based test, return the result in time and help patients weigh benefit against risks, including myelosuppression. The FDA reviewed the application with Australian and Canadian regulators through Project Orbis; their reviews remain ongoing. For patients, the next measure is how reliably testing turns this regulatory decision into a treatment decision.
The drug middleman has to open the books
The US Department of Labor has finalised a rule requiring pharmacy benefit managers and certain affiliates to disclose fees and compensation to fiduciaries of large, self-insured employer health plans. The disclosures cover how these intermediaries are paid through arrangements involving drug manufacturers, pharmacies and others. More detailed requirements apply to plan years beginning in July 2027, giving employers information to examine when they negotiate and monitor contracts. (US Department of Labor)
For years, an employer could pay the prescription-drug bill without a clear view of every payment flowing to the firm managing it. Disclosure gives plan fiduciaries a stronger basis to challenge fees, rebates and incentives that may affect their members’ costs. It does not itself lower a patient’s copayment, and the detailed rule has a defined scope. The test will come when employers use the information—and when workers can see whether a better contract changes what they pay.
The algorithm has met 53 health ministers
All 53 Member States in the WHO European Region have adopted its first roadmap for AI in health, covering 2026–2033. It calls for work across governance, legal and ethical safeguards, data infrastructure, workforce skills and evaluation in real health systems. WHO says the roadmap is accompanied by an implementation guide for countries with different levels of digital readiness. (WHO Europe)
A roadmap is a political commitment, not a clinical safety certificate for every tool a hospital might buy. Governments now have to decide who evaluates an AI system, what data it can use, how clinicians can question its output and who is accountable when performance changes. Patients and health workers need those answers before scale turns a local error into a system-wide one. Watch the national budgets, rules and evaluations that follow this unanimous vote.
Africa wants the keys to its health data
African Union Member States have validated a proposed continental health-data governance framework. It seeks common safeguards for privacy, security and ethical use while allowing countries to retain oversight of their own systems. Africa CDC describes a federated approach through which information could be shared across borders for care and disease surveillance without handing control of national data systems to one centre. (Africa CDC)
For researchers and technology developers, this could create clearer terms for cooperation; for patients, the stakes are trust and protection against misuse. Validation is an important step, but the framework still needs finalisation, consideration through African Union processes and national implementation, anticipated from 2027. The hard question is how to make useful data travel while keeping rights, responsibility and public benefit anchored where those data originate.
Japan asks a gene therapy for its receipts
Japan’s health-insurance council has moved to restart its cost-effectiveness analysis of Zolgensma, the one-time gene therapy for spinal muscular atrophy. The analysis was paused because the evidence available at authorisation did not adequately describe long-term effectiveness in Japanese clinical practice. Five years of additional data collection have now ended; the council’s documents set out a return to analysis, beginning with renewed pre-analysis discussions. (Japan’s health ministry)
This is a consequential bargain for rare-disease medicine. Early access can be justified when families have little time and few options, while a health system still needs to learn how long the benefit lasts relative to an exceptional price. Restarting the assessment is not a finding that the therapy lacks value, nor is it a new price decision. The company’s analysis and the public review come next. Other payers will be watching how Japan uses evidence gathered after access began.
A rare-disease medicine leaves the refrigerator
Brazil’s regulator has approved Evrysdi Go, a tablet formulation of risdiplam for eligible people with 5q spinal muscular atrophy aged over two years and weighing at least 20 kg. Risdiplam was already available in another form. Anvisa says the new tablet can be swallowed or dispersed in water and, unlike the previously approved formulation, does not require professional reconstitution or refrigeration. (Anvisa)
A formulation change rarely gets the applause reserved for a new molecule. Families living with a long-term genetic condition may judge it by a different standard: fewer preparation steps and simpler storage can make a treatment easier to fit into daily life. Registration does not answer every question about supply or coverage, and the tablet is only for the approved population. Still, this is a reminder that the design of delivery matters alongside the design of the drug.
The tumour found an escape route. The trial followed
A Phase III trial published during ESMO tested what happens after EGFR-mutated lung cancer progresses on osimertinib and the tumour shows MET overexpression or amplification. Among 338 randomised patients, continuing osimertinib with the MET inhibitor savolitinib improved progression-free and overall survival compared with platinum–pemetrexed chemotherapy. Serious or severe treatment-emergent adverse events remained common in both groups. (New England Journal of Medicine)
Resistance is often described as a drug failing. Here, a biomarker helped researchers identify a more precise next move. The result matters to patients facing progression, laboratories that must detect MET changes and payers that will be asked to fund both testing and treatment. It is trial evidence for a defined group, with regulatory review and local access still to be worked through. Watch whether services can test at progression quickly enough for the result to guide care
The November watch
| 9–12 November — Europe’s next medicine opinions. |
| The EMA’s CHMP meets; watch its recommendations and safety discussions. An opinion is not yet a European Commission authorisation. (EMA) European Medicines Agency (EMA) |
| 12–15 November — Oncology meets in Changsha. |
| The China Congress of Integrative Oncology convenes. Watch how clinical evidence, diagnostics and international cooperation are translated into workable care pathways. (Congress programme) 2026cchio.sciconf.cn |
Follow the last-mile conversation!
IPM Alliance tracks the decisions, bottlenecks and implementation gaps shaping personalised medicine access. Follow us for briefings, events, policy signals and practical insights from across regions and disease areas.
We want to hear from you
When a patient becomes eligible for personalised care, where does the system most often lose them: identification, testing, referral, reimbursement, delivery capacity or equity?
Know someone who should be reading this?
IPM Brief is built for people working where science, policy and patient access collide. If one colleague would find this useful, forward it to them and help bring them into the conversation.
International Alliance for Personalised Medicine
Avenue de l’Armée / Legerlaan 10, 1041 Brussels, Belgium
